- Denosumab is linked to increased bone mineral density (BMD) and decreased fracture risk in patients with hormone receptor-positive (HR+) breast cancer who have aromatase inhibitor (AI)-induced bone loss.
Why this matters
- AIs may be responsible for around 5% bone loss per year.
- This network meta-analysis is the first to compare bone-modifying agents (BMAs) in this population.
- Although the authors decline to specify the best BMA, they note that denosumab is more advantageous than other BMAs studied (denosumab or bisphosphonates zoledronate, risedronate).
- Network meta-analysis of denosumab, zoledronate, and risedronate (16 randomized controlled trials; N=7699).
- Funding: None disclosed.
- Denosumab vs risedronate was linked to higher BMD (mean difference [MD], 3.29; 95% CI, 2.29-4.29) in the lumbar spine at 1 year.
- Zoledronate vs risedronate also did well (MD, 3.10; 95% CI, 2.23-3.98).
- Denosumab vs no treatment was linked to lower fracture risk: relative risk (RR), 0.51; 95% CI, 0.38-0.67).
- Risedronate vs no treatment also was linked to lower fracture risk: RR, 0.54 (95% CI, 0.35-0.83).
- Heterogeneity across studies.